Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.69 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250842 | 0.84 | CNR2 (0.63) | CNR2CNR1KMT2AALDH1A1MEN1 | |
| SCHEMBL2737025 | 0.83 | CNR2 (0.72) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL2737046 | 0.80 | CNR2 (0.77) | CNR2CNR1KMT2AALDH1A1MEN1 | |
| SCHEMBL216666 | 0.80 | CNR2 (0.83) | CNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL13531340 | 0.80 | CNR2 (0.78) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL218313 | 0.79 | CNR2 (0.67) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL2737045 | 0.79 | CNR2 (0.83) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL2737029 | 0.79 | CNR2 (0.78) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL13531299 | 0.78 | CNR2 (0.77) | CNR2CNR1NPC1KMT2AALDH1A1 | |
| SCHEMBL2737037 | 0.78 | CNR2 (0.81) | CNR2CNR1NPC1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885CNR1 2/4885NPC1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.